Novel oral anticoagulants (NOACs) have been associated with multiple safety benefits compared with vitamin
K antagonists in patients with diseases at high thromboembolic potential, including nonvalvular atrial fibrillation.
Although these agents have several distinct advantages, they are limited by the lack of a proven antidote, which
may represent a major concern in case of life-threatening bleeding. Several different drugs and compounds are
currently under investigation as reversing agents of NOACs. This article provides an overview of potential
NOACs antidotes, including recent patents of emerging compounds.
Keywords: Antidote, direct inhibitor Factor IIa, direct inhibitor Factor Xa, novel oral anticoagulants, reversing agent.
Rights & PermissionsPrintExport